Patents by Inventor Christoph Ladel

Christoph Ladel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polypeptides binding ADAMTS5, MMP13 and aggrecan
    Patent number: 11813307
    Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: November 14, 2023
    Assignees: MERCK PATENT GMBH, ABLYNX NV
    Inventors: Soren Steffensen, Gerald Beste, Hans Guehring, Lars Toleikis, Christoph Ladel, Sven Lindemann, Roland Kellner, Ralf Guenther
  • AGGRECAN BINDING IMMUNOGLOBULINS
    Publication number: 20230312694
    Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.
    Type: Application
    Filed: December 23, 2022
    Publication date: October 5, 2023
    Applicants: Ablynx N.V., Merck Patent GmbH
    Inventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
  • Aggrecan binding immunoglobulins
    Patent number: 11603401
    Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: March 14, 2023
    Assignees: Ablynx N.V., Merck Patent GmbH
    Inventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
  • AGGRECAN BINDING IMMUNOGLOBULINS
    Publication number: 20220089703
    Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.
    Type: Application
    Filed: June 4, 2018
    Publication date: March 24, 2022
    Applicants: Ablynx N.V., Merck Patent GmbH
    Inventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
  • AGGRECAN BINDING IMMUNOGLOBULINS
    Publication number: 20210115117
    Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.
    Type: Application
    Filed: June 4, 2018
    Publication date: April 22, 2021
    Applicants: Ablynx N.V., Merck Patent GmbH
    Inventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
  • POLYPEPTIDES BINDING ADAMTS5, MMP13 AND AGGRECAN
    Publication number: 20210008160
    Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).
    Type: Application
    Filed: June 4, 2018
    Publication date: January 14, 2021
    Applicants: Merck Patent GmbH, ABLYNX NV
    Inventors: Soren STEFFENSEN, Gerald BESTE, Hans GUEHRING, Lars TOLEIKIS, Christoph LADEL, Sven LINDEMANN, Roland KELLNER, Ralf GUENTHER
  • MMP13 BINDING IMMUNOGLOBULINS
    Publication number: 20200190216
    Abstract: The present invention relates to immunoglobulins that specifically bind MMP13 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit an activity of MMP13 and preferably are also stable.
    Type: Application
    Filed: June 4, 2018
    Publication date: June 18, 2020
    Applicants: Merck Patent GmbH, ABLYNX NV
    Inventors: Francis DESCAMPS, Gerald BESTE, Guy HERMANS, Hans GUEHRING, Lars TOLEIKIS, Christoph LADEL
  • AGGRECAN BINDING IMMUNOGLOBULINS
    Publication number: 20200140532
    Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.
    Type: Application
    Filed: June 4, 2018
    Publication date: May 7, 2020
    Applicant: Ablynx N.V.
    Inventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
  • Treatment of bacterial diseases of the respiratory organs
    Publication number: 20120010215
    Abstract: The invention relates to inhalable quinolonecarboxylic acid derivative compositions for local control of diseases of the respiratory organs, in particular of lung diseases.
    Type: Application
    Filed: July 28, 2011
    Publication date: January 12, 2012
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Rainer Endermann, Harald Labischinski, Christoph Ladel, Uwe Petersen, Ben Newton
  • Treatment of bacterial diseases of the respiratory organs
    Patent number: 8034817
    Abstract: The invention relates to inhalable quinolonecarboxylic acid derivative compositions for local control of diseases of the respiratory organs, in particular of lung diseases.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: October 11, 2011
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Rainer Endermann, Harald Labischinski, Christoph Ladel, Uwe Petersen, Ben Newton
  • Uracil-thioether
    Publication number: 20060122201
    Abstract: The invention relates to uracil-thioethers, pharmaceutical compositions containing said compounds and to a method for the production thereof. The invention also relates to the use of said substances in the treatment of diseases in humans and animals.
    Type: Application
    Filed: February 14, 2003
    Publication date: June 8, 2006
    Inventors: Niels Svenstrup, Alexander Kuhl, Dietmar Flubacher, Michael Brands, Kerstin Ehlert, Christoph Ladel, Michael Ottneder, Jorg Keldenich, Marcus Bauser
  • Piperidine ouracil used as a medicament for treating bacterial infections
    Publication number: 20060100224
    Abstract: The invention relates to piperidine ouracil and a method for the production thereof in addition to the use thereof in the production of medicaments for treating and/or in the prophylaxis of diseases, especially bacterial diseases.
    Type: Application
    Filed: February 13, 2003
    Publication date: May 11, 2006
    Inventors: Niels Svenstrup, Alexander Kuhl, Dietmar Flubacher, Michael Brands, Kerstin Ehlert, Christoph Ladel, Michael Otteneder, Jorg Keldenich
  • Treatment of bacterial diseases of the respiratory organs
    Publication number: 20040254194
    Abstract: The invention relates to inhalable quinolonecarboxylic acid derivative compositions for local control of diseases of the respiratory organs, in particular of lung diseases.
    Type: Application
    Filed: February 10, 2004
    Publication date: December 16, 2004
    Applicant: Bayer HealthCare AG
    Inventors: Rainer Endermann, Harald Labischinski, Christoph Ladel, Uwe Petersen, Ben Newton